Cargando…

Cell-Based Therapy for Severe COVID-19 Patients: Clinical Trials and Cost-Utility

The race among countries and companies to develop efficacious vaccines and therapeutics for the COVID-19 is ongoing fast, with many trials underway. Among this, cell-based therapy is focused on moderate to severe phases of COVID-19, and there have been promising outcomes. Mesenchymal stem cells (MSC...

Descripción completa

Detalles Bibliográficos
Autor principal:	Golchin, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532742/ https://www.ncbi.nlm.nih.gov/pubmed/33009982 http://dx.doi.org/10.1007/s12015-020-10046-1

Ejemplares similares

Stem Cell Therapy Potency in Personalizing Severe COVID-19 Treatment
por: Basiri, Arefeh, et al.
Publicado: (2021)

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future
por: Golchin, Ali, et al.
Publicado: (2020)

Effects of Continuous Care Model Based Non-Pharmacological Intervention on Sleep Quality in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Clinical Trial
por: Khosravan, Shahla, et al.
Publicado: (2015)

Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis
por: Congly, Stephen E., et al.
Publicado: (2021)

Critical roles of TLRs on the polarization of mesenchymal stem cells for cell therapy of viral infections: a notice for COVID-19 treatment
por: Gholizadeh-Ghaleh Aziz, Shiva, et al.
Publicado: (2021)

Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma
por: Buendía, Jefferson Antonio, et al.
Publicado: (2021)

A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer
por: De Bleser, Elise, et al.
Publicado: (2020)

Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial
por: Prada, Sergio I, et al.
Publicado: (2023)

Cost Utility of Vaccination Against COVID-19 in Brazil
por: Fernandes, Ricardo Ribeiro Alves, et al.
Publicado: (2022)

An Assessment of the Cost-Utility of Therapy for Psoriasis
por: Weiss, Stefan C, et al.
Publicado: (2006)

Cost-utility and cost-effectiveness of individual placement support and cognitive remediation in people with severe mental illness: Results from a randomized clinical trial
por: Christensen, Thomas Nordahl, et al.
Publicado: (2020)

Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial
por: Saeedi-Boroujeni, Ali, et al.
Publicado: (2022)

Severe COVID-19: Drugs and Clinical Trials
por: Ceja-Gálvez, Hazael Ramiro, et al.
Publicado: (2023)

Clinical progress in MSC-based therapies for the management of severe COVID-19
por: Rossello-Gelabert, Maria, et al.
Publicado: (2022)

Cost-Utility and Cost-Effectiveness of Internet-Based Treatment for Adults With Depressive Symptoms: Randomized Trial
por: Warmerdam, Lisanne, et al.
Publicado: (2010)

New COVID-19 Vaccine: What about Cost and Utility?
por: Yasri, Sora, et al.
Publicado: (2022)

Protocol for a cost–utility analysis of neurostimulation and intensive camp-based therapy for children with perinatal stroke and hemiparesis based on a multicentre clinical trial
por: Berrigan, Patrick, et al.
Publicado: (2021)

Utility of the HScore for Predicting COVID-19 Severity
por: Hannah, William, et al.
Publicado: (2022)

EE299 Cost Analysis of High-Flow Oxygen Therapy Compared with Conventional Oxygen Therapy in Severe COVID-19 in Colombia: Data from a Randomized Clinical Trial
por: Prada, S., et al.
Publicado: (2023)

Cost Utility of Bronchial Thermoplasty for Severe Asthma: Implications for Future Cost-Effectiveness Analyses Based on Phenotypic Heterogeneity
por: Keim-Malpass, Jessica, et al.
Publicado: (2022)

Utilization, Cost, and Affordability of Antihypertensive Therapy in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2021)

A Cost-Utility Analysis of Remote Pulse-Oximetry Monitoring of Patients With COVID-19
por: Padula, William V., et al.
Publicado: (2022)

PIN21 The Cost-Utility of Remote Pulse-Oximeter Monitoring of COVID19 Patients
por: Crawford, S., et al.
Publicado: (2021)

534. Healthcare Resource Utilization and Costs among Patients with COVID-19 in the United States
por: Liu, Gui, et al.
Publicado: (2023)

Cardiac Resynchronisation Therapy in Patients with Moderate to Severe Heart Failure in Germany: A Cost-Utility Analysis of the Additional Defibrillator
por: Hadwiger, Moritz, et al.
Publicado: (2020)

Utility of Presepsin and Interferon-λ3 for Predicting Disease Severity and Clinical Outcomes in COVID-19 Patients
por: Lee, Gun-Hyuk, et al.
Publicado: (2023)

Clinical Trial End Points in Severe COVID-19
por: Desai, Aakash, et al.
Publicado: (2020)

Cost–utility analysis of telemonitoring versus conventional hospital-based follow-up of patients with pacemakers. The NORDLAND randomized clinical trial
por: Lopez-Villegas, Antonio, et al.
Publicado: (2020)

Stent thrombosis during COVID‐19 pandemic: A case series
por: Montaseri, Mohammad, et al.
Publicado: (2022)

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial
por: ter Wee, Marieke M, et al.
Publicado: (2017)

Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19
por: Raychaudhuri, Deblina, et al.
Publicado: (2022)

Cost-Utility of Attachment-Based Compassion Therapy (ABCT) for Fibromyalgia Compared to Relaxation: A Pilot Randomized Controlled Trial
por: D’Amico, Francesco, et al.
Publicado: (2020)

Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial
por: Alavi Darazam, Ilad, et al.
Publicado: (2021)

Potential of regulatory T-cell-based therapies in the management of severe COVID-19
por: Stephen-Victor, Emmanuel, et al.
Publicado: (2020)

Clinical Utilization and Cost of Thrombophilia Testing in Patients with Venous Thromboembolism
por: Gaddh, Manila, et al.
Publicado: (2020)

Remdesivir cost effective for severe COVID-19 in China
Publicado: (2021)

Significance of Cardiac Troponins as an Identification Tool in COVID-19 Patients Using Biosensors: An Update
por: Rasmi, Yousef, et al.
Publicado: (2022)

Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China
por: Zhang, Chunxiang, et al.
Publicado: (2016)

Efficacy of convalescent plasma therapy in severe COVID-19 patients
por: Akay Cizmecioglu, Hilal, et al.
Publicado: (2021)

Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial
por: Alavi Darazam, Ilad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lr5ipsua2h4e1cr0318ohtmggf